How India Exports Ras to the World

The United States, accounting for 29.3% of "Ras" exports from India, represents the largest market for this product. The U.S. Food and Drug Administration (FDA) requires that all pharmaceutical products, including "Ras," obtain approval through the Abbreviated New Drug Application (ANDA) pathway for generic drugs. According to the FDA's Orange Book, the number of approved ANDAs for "Ras" has been steadily increasing, reflecting a competitive market landscape. Recent approvals include applications granted in January 2026 and March 2026, indicating ongoing market entry by new manufacturers.

Importantly, there are currently no FDA import alerts or restrictions specific to "Ras," facilitating uninterrupted trade. The substantial number of active Indian exporters (1,156) underscores India's significant role in supplying "Ras" to the U.S. market. Compliance with FDA regulations, including adherence to Current Good Manufacturing Practices (cGMP), is imperative for maintaining market access.

In the European Union (EU) and the United Kingdom (UK), "Ras" is subject to stringent regulatory oversight. The European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) require that pharmaceutical products obtain marketing authorization prior to commercialization. This process involves a comprehensive evaluation of the product's quality, safety, and efficacy.

As of September 2025, the EMA has updated its guidelines to align with the latest EU Good Manufacturing Practice (GMP) requirements, emphasizing the need for robust quality management systems. Similarly, the MHRA has implemented new pharmacovigilance requirements effective from October 2025, necessitating enhanced monitoring and reporting of adverse drug reactions. Indian exporters must ensure compliance with these evolving standards to maintain access to these markets.

The World Health Organization (WHO) includes "Ras" in its 24th Model List of Essential Medicines, published in September 2025. This inclusion underscores the medicine's critical role in addressing global health needs. The WHO's prequalification program further provides a benchmark for quality, safety, and efficacy, facilitating procurement by UN agencies and member states.

Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for global market acceptance. These standards ensure consistency in drug quality and are often referenced in regulatory submissions.

In India, "Ras" is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has set a ceiling price for "Ras" at ₹50 per unit, effective from December 2025, to ensure affordability. For exports, the Central Drugs Standard Control Organization (CDSCO) mandates a No Objection Certificate (NOC), which requires detailed documentation of the product's quality and regulatory compliance.

The patent landscape for "Ras" indicates that key patents have expired, allowing for increased generic competition. This has led to a proliferation of manufacturers and a subsequent reduction in prices, benefiting consumers globally. However, ongoing monitoring of patent filings is advisable to anticipate potential market exclusivities that could impact trade dynamics.

In the past 12 months, several significant developments have occurred:

1. API Price Fluctuations: In June 2025, the Directorate General of Foreign Trade (DGFT) reported a 10% increase in the price of active pharmaceutical ingredients (APIs) for "Ras," attributed to supply chain disruptions.

2. Regulatory Approvals: In August 2025, the FDA approved a new generic version of "Ras," expanding the competitive landscape in the U.S. market.

3. Policy Changes: In November 2025, the Indian government introduced new export incentives for pharmaceutical products, including "Ras," to boost international trade.

These developments highlight the dynamic nature of the pharmaceutical industry and the importance of staying informed to navigate the regulatory and market challenges effectively.

India's pharmaceutical industry, including the production of "Ras," heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70-80% of India's API and KSM requirements are sourced from China, creating a significant dependency. This reliance exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and disruptions in Chinese manufacturing.

Recent events have further highlighted this vulnerability. In March 2026, the closure of the Strait of Hormuz due to escalating conflicts led to substantial disruptions in global supply chains, including the pharmaceutical sector. The blockade halted maritime traffic, affecting the transportation of crude oil and petrochemical feedstocks essential for API production. This disruption resulted in increased production costs and logistical challenges for Indian pharmaceutical manufacturers.

The export market for "Ras" from India is notably concentrated among a few key players. The top five exporters—CIPLA LIMITED, INTAS PHARMACEUTICALS LIMITED, MYLAN LABORATORIES LIMITED, MSN LABORATORIES PRIVATE LIMITED, and BIOCON BIOLOGICS INDIA LIMITED—collectively account for 53.6% of total exports. CIPLA LIMITED alone holds a 14.9% share, indicating a significant reliance on a limited number of suppliers.

To mitigate such concentration risks, the Indian government introduced the Production Linked Incentive (PLI) scheme aimed at bolstering domestic API manufacturing and reducing import dependence. This initiative seeks to diversify the supplier base and enhance the resilience of the pharmaceutical supply chain. (pharmanow.live)

Geopolitical tensions have recently led to significant disruptions in global shipping routes critical to the pharmaceutical supply chain. In March 2026, the blockade of the Strait of Hormuz halted maritime traffic, affecting the transportation of crude oil and petrochemical feedstocks essential for API production. This disruption resulted in increased production costs and logistical challenges for Indian pharmaceutical manufacturers.

Additionally, the Red Sea and the Strait of Hormuz have become focal points of asymmetric naval conflicts, leading to further disruptions in maritime traffic. These conflicts have caused shipping delays and increased transportation costs, impacting the timely delivery of pharmaceutical products. (lemonde.fr)

• Diversify API and KSM Sources: Reduce dependency on Chinese imports by developing alternative supply chains, including domestic production and sourcing from other countries.

• Enhance Domestic Manufacturing: Leverage the PLI scheme to strengthen local API and KSM manufacturing capabilities, thereby reducing reliance on imports.

• Strengthen Supplier Relationships: Foster partnerships with multiple suppliers to mitigate risks associated with supplier concentration and ensure a more resilient supply chain.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on the supply chain, enabling proactive risk management.

• Develop Contingency Plans: Create and regularly update contingency plans to address potential disruptions in shipping routes, including identifying alternative transportation methods and routes.

RISK_LEVEL: HIGH